|

Study to Assess the Feasibility of Stopping Prostate Cancer Treatment Early in Elderly Patients

RECRUITINGN/ASponsored by University of Chicago
Actively Recruiting
PhaseN/A
SponsorUniversity of Chicago
Started2026-06
Est. completion2026-12
Eligibility
Age70 Years+
SexMALE
Healthy vol.Accepted
Locations2 sites
View on ClinicalTrials.gov →

NCT06824818

Summary

This study seeks to identify if it is feasible to stop Luteinizing Hormone-Releasing Hormone (LHRH) Agonist Therapy in elderly men with prostate cancer. We hypothesize that elderly prostate cancer patients on long term androgen ablation with LHRH agonists will be permanently castrated and do not require ongoing LHRH agonist therapy. Participants will be monitored by testosterone testing throughout study.

Eligibility

Age: 70 Years+Sex: MALEHealthy volunteers accepted
Inclusion Criteria:

* Prostate cancer with \>3 years of LHRH agonist therapy.
* Age ≥70 years.
* ECOG performance status ≤2
* Baseline testosterone of \< 20 ng/ml
* No prior chemotherapy or Lu-PSMA (unless survival predictions are favorable).
* Ability to understand and sign informed consent.

Exclusion Criteria:

* none

Conditions3

CancerElderlyProstate Cancer

Locations2 sites

The University of Illinois at Chicago (UIC)
Chicago, Illinois, 60607
TBD TBD
UChicago Medicine Comprehensive Cancer Center
Chicago, Illinois, 60637
Cancer Clinical Trial Intake855-702-8222cancerclinicaltrials@bsd.uchicago.edu

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.